hydron;1-(3H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: hydron;1-(3H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;chloride
• 化学式: C15H22ClNO2
• 分子量: 283.79
• InChiKey: MVDJMRCMFUAEQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  41.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(2-Hydroxy-3-isopropylamino-propoxy)-indan-1-ol 、 盐酸 以28%的产率得到
  参考文献：
  名称：

  MURASE KIYOSHI; TAMAZAWA TOSHIYASU; MASE TOSHIYASU; TACHIKAWA SHIRO; SHIO+, CHEM. AND PHARM. BULL. , 1976, 24, NO 3, 552-554

  摘要：

  DOI：

文献信息

• Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0151006B1

  公开（公告）日：1991-08-28
• Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0167371B1

  公开（公告）日：1991-03-06
• EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE
  申请人：Pharmacia Corporation

  公开号：EP1303306B1

  公开（公告）日：2006-06-21
• Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
  申请人：Alexander C. John

  公开号：US20050215537A1

  公开（公告）日：2005-09-29

  A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α,11α-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.
• US4727082A
  申请人：——

  公开号：US4727082A

  公开（公告）日：1988-02-23